CD19
Synonyms
CD19, T-cell surface antigen Leu-12, Differentiation antigen CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, CD19 Antigen, B-Lymphocyte Antigen CD19, CVID3, B4, Antigens, CD19,Description
B-lymphocyte antigen CD19 functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. CD19 decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. CD19 activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca stores. And it is required for normal differentiation of B-1 cells, normal B cell differentiation and proliferation in response to antigen challenges, normal levels of serum immunoglobulins and for production of high-affinity antibodies in response to antigen challenge.
KO Status
F0
Drug Information
Launched drugs: 159
Drugs in clinical trials: 6
Latest Research Phase:Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
CD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology)
IND
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Lymphoma
UBG-T19
Preclinical
Guangzhou Baiji Gene Technology Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
HY-003
HY-003
Preclinical
Heyuan Biotechnology (Tianjin) Co Ltd
Relmacabtagene autoleucel
JWCAR-029
NDA/BLA
Suzhou Yaomingjunuo Biotechnology Co Ltd
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
NCT Number
NCT04089215
NCT03344367
NCT03355859
Intervention Type
Biological
Biological
Biological
Indications
Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma; Follicular Lymphoma
Non Hodgkin Lymphoma
Non Hodgkin Lymphoma
Study Phase
Phase 2
Phase 1
Phase 1
Recruitment Status
Recruiting
Active, not recruiting
Active, not recruiting
Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene)
BG-T19
IND
Guangzhou Baiji Gene Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Tisagenlecleucel
LG-740, CART-19, CTL-019, CART-019
Approved
University Of Pennsylvania, Novartis Pharma Ag
Lymphoma, Large B-Cell, Diffuse, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
NCT Number
NCT03628053
NCT04094311
NCT03570892
NCT03123939
NCT03027739
NCT04161118
NCT03568461
NCT03876769
NCT02445248
NCT02228096
NCT02030834
NCT02030847
NCT04225676
NCT03610724
NCT02435849
NCT04456023
NCT04156659
NCT01747486
NCT02935543
NCT02167360
NCT02794246
NCT01626495
NCT02135406
NCT03630159
NCT02810223
NCT01029366
NCT03101709
NCT04134117
NCT03876028
NCT01551043
NCT02640209
NCT02476734
NCT03601442
NCT02906371
NCT02445222
NCT03642626
Intervention Type
Biological;Drug
Biological
Drug
Biological
Biological
Drug
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Drug
Biological
Biological
Biological
Biological;Drug
Biological
Biological
Biological;Drug
Biological
Biological;Drug
Biological
Biological
Other
Biological
Biological;Drug
Genetic
Drug
Indications
Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Non Hodgkin Lymphoma
Follicular Lymphoma
B-Cell Acute Lymphoblastic Leukemia
Diffuse Large B-cell Lymphoma (DLBCL)
B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
ALL
Non-Hodgkin Lymphoma
Lymphoblastic Leukemia; Acute; High Risk; Childhood
Diffuse Large B-Cell Lymphoma (DLBCL)
B-cell Acute Lymphoblastic Leukemia
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Leukemia, Acute Lymphoblastic
B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia
Multiple Myeloma
B Cell Leukemia; B Cell Lymphoma
Multiple Myeloma
Diffuse Large B-cell Lymphoma
Acute Lymphoblastic Leukemia
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
B Cell Lymphoma
Primary CNS Lymphoma; Refractory Primary CNS Lymphoma; Relapsed Primary CNS Lymphoma
Diffuse Large B-cell Lymphoma
Acute Lymphocytic Leukemia
LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Lymphoma
Acute Lymphoblastic Leukemia (ALL); Diffuse Large B-cell Lymphoma (DLBCL)
Lymphoblastic Leukemia, Acute, Childhood
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
N/A
Recruitment Status
Withdrawn
Recruiting
Recruiting
Completed
Recruiting
Not yet recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Completed
Completed
Completed
Recruiting
Recruiting
Active, not recruiting
Not yet recruiting
Not yet recruiting
Completed
Terminated
Withdrawn
Terminated
Completed
Completed
Recruiting
Unknown status
Completed
Unknown status
Recruiting
Active, not recruiting
Terminated
Terminated
Completed
Available
Active, not recruiting
Recruiting
Recruiting
Loncastuximab tesirine
ADCT-402
NDA/BLA
Adc Therapeutics
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04384484
NCT04699461
NCT03589469
NCT03684694
NCT02669017
NCT02669264
NCT03685344
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Indications
Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma
Diffuse Large B-Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent
Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma
Non-Hodgkin Lymphoma; Burkitt's Lymphoma; Chronic Lymphocytic Leukemia; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Marginal Zone; Waldenstrom Macroglobulinemia; Primary Mediastinal B-cell Lymphoma
Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma
Study Phase
Phase 3
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Recruiting
Completed
Terminated
Terminated
Brexucabtagene autoleucel
KTE-X19
Approved
Kite Pharma Inc
Lymphoma, Mantle-Cell
B-193
B-193
Preclinical
Shanghai Yanyi Biotechnology
Neoplasms
FKC-876
FKC-876
NDA/BLA
Fosun Kate Biotechnology Co Ltd
Lymphoma, B-Cell
RD-301
Preclinical
Nanjing Iaso Biotherapeutics Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD19/CD3
Preclinical
Wuhan Yzy Biopharma
Lymphoma
Axicabtagene ciloleucel
KTE-C19, KTE C19
Approved
Cabaret Biotech
Lymphoma, B-Cell, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03391466
NCT04150913
NCT02601313
NCT03761056
NCT04205838
NCT04359784
NCT04002401
NCT04531046
NCT03105336
NCT02926833
NCT02614066
NCT00924326
NCT04314843
NCT03704298
NCT02348216
NCT02625480
NCT04257578
NCT04432506
NCT03624036
NCT04608487
NCT03153462
NCT04162756
NCT03642626
Intervention Type
Biological;Drug
Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological
Biological;Drug
Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological;Drug
Biological
Biological;Drug
Drug
Indications
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non Hodgkin Lymphoma; Neurotoxicity; Neurotoxicity Syndromes; Cytokine Release Syndrome
Relapsed/Refractory Mantle Cell Lymphoma
B-cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Progressive Disease; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
B-Cell Non-Hodgkin Lymphoma
Refractory Large B-cell Lymphoma
B-Cell Lymphoma Refractory; B-cell Lymphoma Recurrent
Follicular Lymphoma; Marginal Zone Lymphoma; Indolent Non-Hodgkin Lymphoma
Refractory Diffuse Large B Cell Lymphoma
Acute Lymphoblastic Leukemia
Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma; Mantle Cell
Relapsed/Refractory Large B-cell Lymphoma
Relapsed/Refractory Large B-cell Lymphoma
Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL); Primary Mediastinal B-cell Lymphoma (PMBCL); High Grade B-cell Lymphoma (HGBCL)
Acute Lymphoblastic Leukemia; Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma
B-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Lymphoma; Lymphoma Cns
Relapsed/Refractory Diffuse Large B Cell Lymphoma; Relapsed/Refractory Primary Mediastinal B Cell Lymphoma; Relapsed/Refractory Transformed Follicular Lymphoma; Relapsed/Refractory High-Grade B-Cell Lymphoma
Relapse/Refractory Mantle Cell Lymphoma
Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
Study Phase
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
N/A
N/A
N/A
Recruitment Status
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Not yet recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Available
Available
Recruiting
Lisocabtagene maraleucel (Celgene/Juno Therapeutics)
JCAR-017, Liso-Cel
NDA/BLA
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children'S Research Institute, Memorial Sloan Kettering Cancer Center
Lymphoma, B-Cell, Lymphatic Diseases, Immunoproliferative Disorders, Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03575351
NCT03483103
NCT03484702
NCT04245839
NCT03744676
NCT03310619
NCT03743246
NCT03331198
NCT02028455
NCT03186118
NCT02631044
NCT03436771
NCT04400591
Intervention Type
Drug;Genetic
Biological
Drug
Drug
Biological
Biological;Drug
Drug
Biological
Biological
Biological
Biological
Genetic
Biological
Indications
Lymphoma, Non-Hodgkin
Lymphoma, Non-Hodgkin; Lymphoma, Nonhodgkin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Lymphoma, Non-Hodgkin
Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Disorder
Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
CD19+ Acute Leukemia
CD 19+ Acute Leukemia
Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle-cell Lymphoma; Primary Mediastinal B-cell Lymphoma
Non Hodgkin Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Study Phase
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
N/A
N/A
Recruitment Status
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Terminated
Temporarily not available
因诺卡替-19细胞
IND
Shenzhen Inno Immunization Co Ltd
Leukemia, Lymphoid
ICTCAR003
ICTCAR003
IND
Sidansai Biotechnology Co Ltd
Leukemia, Biphenotypic, Acute
HY-004 (Juventas)
HY-004 (Juventas)
Preclinical
Heyuan Biotechnology (Tianjin) Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
EBV-CTL (Atara/MSKCC)
EBV-CTL-Atara-MSKCC
Preclinical
Memorial Sloan Kettering Cancer Center
Lymphoproliferative Disorders
Inebilizumab
MEDI-551, 16C4-aFuc
Approved
Medimmune
Myasthenia Gravis, Recurrence, Lymphoma, B-Cell, Hematologic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Scleroderma, Systemic, Multiple Sclerosis, Neuromyelitis Optica, Scleroderma, Localized, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04524273
NCT04540497
NCT02200770
NCT03218163
NCT01453205
NCT04372615
NCT01466153
NCT04174677
NCT00983619
NCT02271945
NCT01585766
NCT00946699
NCT01957579
Intervention Type
Drug
Other;Drug
Other;Drug
Drug
Procedure;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other;Biological
Drug
Indications
Myasthenia Gravis
IgG4 Related Disease
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Multiple Myeloma
Diffuse Large B-Cell Lymphoma
Autoimmune Encephalitis; Encephalitis
Chronic Lymphocytic Leukemia (CLL)
Highly Sensitized Patients on Waiting List for Kidney Transplantation
B-cell Malignancies; Cancer
Relapsed/Refractory Aggressive B-cell Lymphomas
Multiple Sclerosis, Relapsing Forms
Scleroderma
Blood Cancer; Advanced B Cell Malignancies
Study Phase
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
Terminated
Completed
Not yet recruiting
Completed
Active, not recruiting
Completed
Completed
Completed
Completed
Completed
Tafasitamab
XmAb-5574, MOR-208, XENP-5574, MOR-00208
Approved
Xencor
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04680052
NCT02763319
NCT02399085
NCT02639910
NCT04646395
NCT01685021
NCT01685008
NCT04607772
NCT04661007
NCT01161511
NCT04134936
NCT04300803
Intervention Type
Drug
Drug
Drug
Biological;Drug
Drug
Drug
Drug
Drug
Drug
Biological
Drug
Biological
Indications
Follicular Lymphoma; Marginal Zone Lymphoma
Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Marginal Zone Lymphoma
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Non Hodgkins Lymphoma; Diffuse Large B-cell Lymphoma
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Diffuse Large B-cell Lymphoma
DLBCL
Study Phase
Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
N/A
Recruitment Status
Not yet recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Not yet recruiting
Terminated
Active, not recruiting
Recruiting
Not yet recruiting
Completed
Active, not recruiting
Approved for marketing
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology)
IND
Beijing Yongtai Rec Biotechnology Co Ltd
Blinatumomab
MT-103, AMG-103, MEDI-538, BiTE-MT-103, bscCD19xCD3
Approved
Amgen Inc
Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03643276
NCT03914625
NCT03476239
NCT02101853
NCT02393859
NCT04530565
NCT02013167
NCT02003222
NCT02910063
NCT03117751
NCT04554485
NCT03739814
NCT04334993
NCT04688983
NCT03523429
NCT01207388
NCT02744768
NCT02807883
NCT04546399
NCT03709719
NCT02811679
NCT03109093
NCT04448834
NCT03931642
NCT03480438
NCT01741792
NCT04556084
NCT03121534
NCT03263572
NCT03849651
NCT03023878
NCT02997761
NCT03298412
NCT03982992
NCT02143414
NCT02790515
NCT04044560
NCT02000427
NCT01466179
NCT03518112
NCT03541083
NCT01209286
NCT00560794
NCT03367299
NCT04329325
NCT02877303
NCT02458014
NCT03114865
NCT01371630
NCT02412306
NCT00676871
NCT03160079
NCT03512405
NCT01471782
NCT04521231
NCT03340766
NCT03072771
NCT03605589
NCT04524455
NCT02568553
NCT03751709
NCT00274742
NCT02961881
NCT02879695
NCT00538096
NCT03173430
NCT02187354
NCT03117621
NCT03318770
Intervention Type
Drug
Biological;Radiation;Drug
Drug
Procedure;Other;Biological;Radiation;Drug
Drug
Biological;Drug
Drug
Procedure;Other;Biological;Drug
Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Drug
Procedure;Drug
Biological;Radiation;Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological;Drug
Biological;Drug;Device
Drug
Biological;Drug
Drug
Drug
Other;Biological;Drug
Biological;Drug;Device
Biological
Drug
Biological
Other;Biological;Drug
Drug
Biological
Biological
Drug
Biological;Drug
Other;Biological;Drug
Other;Biological
Drug
Other;Biological;Drug
Drug
Drug
Drug
Other;Biological
Biological
Drug
Drug
Procedure;Drug
Drug
Drug
Biological;Drug
Other;Drug
Biological
Drug
Biological
Drug
Drug
Other;Drug
Drug
Indications
Acute Lymphoblastic Leukemia, Pediatric
B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Leukemia, Acute Lymphoblastic
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
B-Cell Non Hodgkin Lymphoma
Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia, Acute, Adult; Ph Negative ALL; Newly Diagnosed
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
Philadelphia-Negative ALL; High-Risk Cancer
Acute Lymphoblastic Leukemia, Adult
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
B-cell Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Down Syndrome; Recurrent B Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, Adult B-Cell
Non-Hodgkin Lymphoma
ALL, Recurrent, Adult
B-cell Acute Lymphoblastic Leukemia
Richter Syndrome
B-Precursor ALL
Diffuse Large B-cell Lymphoma
B-cell Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
Hematopoietic/Lymphoid Cancer; Richter's Transformation
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia; t(9;22)
Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); NK-Cell Leukemia; Hodgkin Lymphoma; Non Hodgkin Lymphoma (NHL); Juvenile Myelomonocytic Leukemia (JMML); Chronic Myeloid Leukemia (CML)
High-risk Diffuse Large B-Cell Lymphoma
Adult B Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive
High-risk Diffuse Large B-cell Lymphoma
B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation; B-Cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia in Remission; Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myeloid Sarcoma; Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Myelodysplastic Syndrome (MDS); Non-Hodgkin Lymphoma (NHL)
B-cell Adult Acute Lymphoblastic Leukemia; Stem Cell Leukemia; Minimal Residual Disease
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
ALL, Adult
B-ALL
Acute Lymphoblastic Leukemia
Acute Lymphoid Leukemia; Philadelphia Chromosome-Negative B-Cell Precursor
Acute Lymphoblastic Leukemia; Philadelphia Chromosome-Positive
B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma
Adult Acute Lymphoblastic Leukemia in Complete Remission; B Acute Lymphoblastic Leukemia; Minimal Residual Disease; Philadelphia Chromosome Positive
Acute Lymphoblastic Leukemia; B-cell Non Hodgkin Lymphoma; Pre B-Cell Acute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Untreated Adult Acute Lymphoblastic Leukemia
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
B-Cell Acute Lymphoblastic Leukemia, Adult
CD19 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
B Cell Precursor Acute Lymphoblastic Leukemia
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Diffuse Large B Cell Lymphoma
Leukemia, B-cell; Lymphoma, B-Cell
Acute Lymphoblastic Leukemia
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Grade 3b Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mediastinal Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Mediastinal Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Small Lymphocytic Lymphoma
B-Cell Acute Lymphoblastic Leukaemia; ALL, Adult; B-ALL
Non-Hodgkin's Lymphoma, Relapsed
Non-Hodgkin's Lymphoma
Recurrent B Acute Lymphoblastic Leukemia; Recurrent Mixed Phenotype Acute Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Mixed Phenotype Acute Leukemia
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin
Multiple Myeloma
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Blincyto Use in Routine Clinical Practice
Acute Lymphoblastic Leukemia
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
N/A
N/A
N/A
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Terminated
Active, not recruiting
Completed
Recruiting
Recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Recruiting
Completed
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Completed
Not yet recruiting
Active, not recruiting
Recruiting
Recruiting
Completed
Recruiting
Terminated
Recruiting
Recruiting
Recruiting
Not yet recruiting
Completed
Completed
Recruiting
Recruiting
Completed
Completed
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Completed
Withdrawn
Recruiting
Recruiting
Completed
Recruiting
Active, not recruiting
Recruiting
Suspended
Recruiting
Recruiting
Recruiting
Completed
Recruiting
Recruiting
Withdrawn
Terminated
No longer available
Recruiting
Not yet recruiting
GB5005 chimeric antigen receptor T cell therapy (Genbase)
IND
Shanghai Genbase Biotechnology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Obexelimab
AMG-729, XmAb-5871
Phase 3 Clinical
Xencor
Immunoglobulin G4-Related Disease, Arthritis, Rheumatoid, Autoimmune Diseases, Lupus Erythematosus, Systemic
NCT Number
NCT02725476
NCT02725515
NCT02867098
Intervention Type
Biological
Biological
Drug
Indications
IgG4-RD
Systemic Lupus Erythematosus
Healthy Volunteers
Study Phase
Phase 2
Phase 2
Phase 1
Recruitment Status
Completed
Completed
Completed
CD19 CAR-T cell therapy (National University of Malaysia)
Phase 3 Clinical
National University Of Malaysia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03937544
Intervention Type
Biological;Drug
Indications
Relapsed B Acute Lymphoblastic Leukaemia; Refractory B Acute Lymphoblastic Leukaemia
Study Phase
Phase 2/Phase 3
Recruitment Status
Recruiting
Anti-CD19 CAR T-cell therapy (Sheba Medical Center)
Phase 3 Clinical
Chaim Sheba Medical Center At Tel Hashomer
Leukemia, Myeloid, Acute
NCT Number
NCT04257175
NCT02772198
Intervention Type
Biological
Biological
Indications
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia, B-precursor; Non-Hodgkin Lymphoma, B-cell
Study Phase
Phase 2/Phase 3
Phase 1/Phase 2
Recruitment Status
Recruiting
Recruiting
Anti-CD19 CAR T-cell therapy (Fujian Medical University)
Phase 3 Clinical
Fujian Medical University
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma
IM19CAR-T
Phase 2 Clinical
Beijing Yimiao Medical Technology Co Ltd
Leukemia, Hematologic Neoplasms, Lymphoma, Non-Hodgkin
NCT Number
NCT03142646
NCT03173417
NCT04440436
NCT03528421
NCT03344705
NCT04336501
Intervention Type
Biological
Biological;Drug
Drug
Biological;Drug
Biological;Drug
Biological
Indications
Leukemia
Leukemia
NHL
Non Hodgkin Lymphoma
Hematological Malignancies
Leukemia
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
N/A
Recruitment Status
Unknown status
Completed
Recruiting
Unknown status
Recruiting
Recruiting
CTL-119
CTL-119
Phase 2 Clinical
University Of Pennsylvania, Novartis Pharma Ag
Lymphoma, Large B-Cell, Diffuse, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
HuCART19
Phase 2 Clinical
National Cancer Institute, Kite Pharma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03792633
NCT02374333
NCT03620058
NCT02659943
Intervention Type
Biological
Biological
Biological
Biological;Drug
Indications
Acute Lymphoid Leukemia
Acute Lymphocytic Leukemia; Diffuse Large Cell Lymphoma
Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
Lymphoma, B-Cell; Lymphoma, Non-hodgkins
Study Phase
Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh)
Phase 2 Clinical
National Institute Of Allergy And Infectious Diseases, University Of Pittsburgh
Immunologic Deficiency Syndromes
NCT Number
NCT03330795
Intervention Type
Biological
Indications
Primary Immunodeficiency; PID
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals)
CARCIK-CD19, CIK-CAR.CD19
Phase 2 Clinical
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD19 chimeric antigen receptor T cell therapy (Takara Bio)
TBI-1501
Phase 2 Clinical
Memorial Sloan Kettering Cancer Center, Takara Bio
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03155191
Intervention Type
Biological
Indications
Lymphoblastic Leukemia, Acute Adult
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine)
yinnuokati-19
Phase 2 Clinical
Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
PCAR-119 (PersonGen Biomedicine)
PCAR-119
Phase 2 Clinical
Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, Prolymphocytic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02892695
Intervention Type
Biological
Indications
Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; B-cell Prolymphocytic Leukemia; Diffuse Large Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Unknown status
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals)
BPX-401
Phase 2 Clinical
Bellicum Pharmaceuticals, Ospedale Pediatrico Bambino Gesu
Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma
ALLO-501
ALLO-501
Phase 2 Clinical
Cellectis
Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
NCT Number
NCT04416984
NCT02735083
NCT03939026
Intervention Type
Biological;Drug;Genetic
Biological
Biological;Drug;Genetic
Indications
Relapsed/Refractory Large B Cell Lymphoma
Advanced Lymphoid Malignancies
Relapsed/Refractory Large B Cell Lymphoma; Relapsed/Refractory Follicular Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Recruitment Status
Recruiting
Enrolling by invitation
Recruiting
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology)
SENL-B19
Phase 2 Clinical
Hebei Senlang Biological Technology Co Ltd
Leukemia, Lymphoma, B-Cell, Leukemia, B-Cell, Lymphoma
NCT Number
NCT02963038
NCT03312205
NCT03121625
Intervention Type
Biological
Biological
Biological
Indications
B-Cell Leukemia; B-Cell Lymphoma
Leukemia; Lymphoma; Multiple Myeloma of Bone (Diagnosis)
Leukemia; Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Recruitment Status
Recruiting
Recruiting
Recruiting
AUTO-1
AUTO1, AUTO-1
Phase 2 Clinical
University College London
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04404660
NCT02935257
NCT02443831
Intervention Type
Biological
Biological
Procedure;Biological;Drug
Indications
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Leukemia, Lymphoblastic, Acute, Lymphoma
Acute Lymphoblastic Leukemia; Burkitt Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
BinD-19 (Shenzhen BinDeBio)
BinD-19
Phase 2 Clinical
Shenzhen Bindebio Ltd
Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03265106
NCT03156101
Intervention Type
Biological
Biological
Indications
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood; Refractory B-cell Acute Lymphoblastic Leukemia, Childhood; Relapsed/Refractory B-cell Lymphoma, Childhood
Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed／Refractory B-cell Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Recruitment Status
Recruiting
Active, not recruiting
GNR-084
GNR-084
Phase 2 Clinical
Generium Pharmaceuticals, Iontas
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04601584
Intervention Type
Biological
Indications
B-precursor Acute Lymphoblastic Leukemia; ALL; GNR-084
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
GTB-1550
DT-2219, OXS-1550, DT-2219ARL, IND-100780
Phase 2 Clinical
University Of Minnesota
Leukemia, Lymphoma, B-Cell
NCT Number
NCT02370160
NCT00889408
Intervention Type
Biological
Biological
Indications
Refractory B-Lineage Leukemia; Relapsed B-Lineage Leukemia; Refractory B-Lineage Lymphoma; Relapsed B-Lineage Lymphoma
Leukemia; Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Completed
Completed
anti-CD19 CAR T-cell (Henan Cancer Hospital)
Phase 2 Clinical
Shenzhen Prekin Biopharmaceutical Co Ltd, Henan Provincial Cancer Hospital
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute)
4SCAR-19
Phase 2 Clinical
Shenzhen Geno-Immune Medical Institute
Lymphoma, B-Cell
NCT Number
NCT04429438
Intervention Type
Biological
Indications
B Cell Lymphoma (BCL)
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital)
Phase 2 Clinical
Pla General Hospital
Leukemia, Lymphoma, B-Cell
NCT Number
NCT03398967
Intervention Type
Biological
Indications
B Cell Leukemia; B Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR-T cell therapy (Juventas)
CNCT19, CNCT-19, HY001
Phase 2 Clinical
Heyuan Biotechnology (Tianjin) Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04586478
NCT04684147
NCT04690192
NCT04230473
NCT04011293
Intervention Type
Biological
Biological
Biological;Drug
Biological
Biological
Indications
Non-Hodgkin's Lymphoma
Relapsed or Refractory Acute Lymphoblastic Leukemia
Large B-cell Lymphoma
Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Hematological Malignancies
Study Phase
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Early Phase 1
Recruitment Status
Recruiting
Not yet recruiting
Recruiting
Recruiting
Recruiting
Anti-CD19 CAR T-cell therapy (Nanjing Medical University)
XLCART-001
Phase 2 Clinical
Nanjing Medical University
Lymphoma, B-Cell
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology)
Phase 2 Clinical
Shanghai Zhongshan Hospital, Hrain Biotechnology
Candidiasis, Vulvovaginal, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03720457
NCT03798509
Intervention Type
Drug
Drug
Indications
CD19-positive; Diffuse Large B-cell Lymphoma; Follicular Lymphoma
CD19-positive; Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics)
Phase 2 Clinical
Sidansai Biotechnology Co Ltd, Kunming Medical University, Zhejiang University
Leukemia, Leukemia, Lymphoid, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT03118180
NCT04381741
NCT04661020
NCT02813837
Intervention Type
Biological
Biological
Drug
Biological
Indications
Lymphoma
Diffuse Large B-cell Lymphoma
Non-hodgkin Lymphoma,B Cell
Leukemia, B-Cell; Lymphoma, B-Cell
Study Phase
Phase 1/Phase 2
Phase 1
Early Phase 1
N/A
Recruitment Status
Recruiting
Recruiting
Not yet recruiting
Recruiting
CD19-CART
Phase 2 Clinical
Hrain Biotechnology Co Ltd
Lymphoma, Large B-Cell, Diffuse, Multiple Myeloma, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02652910
NCT02685670
NCT03706547
Intervention Type
Drug
Biological;Drug
Biological;Drug
Indications
Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Multiple Myeloma in Relapse; Multiple Myeloma Progression
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Recruitment Status
Unknown status
Unknown status
Not yet recruiting
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta)
Phase 2 Clinical
University Of Alberta
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03938987
Intervention Type
Biological
Indications
Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL; Relapsed Pediatric ALL
Study Phase
Phase 1/Phase 2
Recruitment Status
Not yet recruiting
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy
GC-197
Phase 2 Clinical
Genxi Biotechnology (Shanghai) Co Ltd
Lymphoma, B-Cell, Leukemia, B-Cell
U-CART (Shanghai Bioray Laboratory Inc)
Phase 2 Clinical
Shanghai Bioray Laboratory Inc
Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD19.CAR T Cells (University Hospital Heidelberg)
Phase 2 Clinical
University Of Heidelberg
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03676504
Intervention Type
Biological;Drug
Indications
Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Pediatric; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
CAR-T 19 cell therapy (University of Pennsylvania)
Phase 2 Clinical
University Of Pennsylvania
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04276870
Intervention Type
Biological
Indications
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL; Infants With Very High Risk KMT2A B-ALL; Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Study Phase
Phase 2
Recruitment Status
Recruiting
3rd-gen-CD19-CAR
3rd-gen-CD19-CAR
Phase 2 Clinical
Bluebird Bio
Lymphoma, B-Cell, Leukemia, B-Cell
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin)
Phase 2 Clinical
The Medical College Of Wisconsin Nonprofit
Neoplasms
NCT Number
NCT04186520
NCT04049383
Intervention Type
Biological
Biological
Indications
Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL)
Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Acute Lymphoblastic Leukemia Recurrent; Acute Lymphoblastic Leukemia Not Having Achieved Remission; Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Recruiting
Recruiting
CD19 CAR-T cell (Pregene)
Phase 2 Clinical
Shenzhen Prekin Biopharmaceutical Co Ltd
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03263208
NCT03146533
NCT03685786
NCT02924753
NCT03101709
Intervention Type
Biological;Drug
Biological;Drug
Biological
Biological;Drug
Biological;Drug
Indications
B-cell Acute Lymphocytic Leukemia
B Cell Lymphoma
Leukemia, Lymphocytic, Acute, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell
B-cell Acute Lymphoblastic Leukemia
B Cell Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Unknown status
Unknown status
Recruiting
Unknown status
Unknown status
TAC01-CD19
TAC01-CD19
Phase 2 Clinical
Triumvira Immunologics
Lymphoma, B-Cell
NCT Number
NCT03880279
Intervention Type
Biological
Indications
Lymphoma, B-Cell
Study Phase
Phase 1/Phase 2
Recruitment Status
Not yet recruiting
AUTO-3
AUTO-3
Phase 2 Clinical
University College London
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03289455
Intervention Type
Biological
Indications
B Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Refractory Childhood Acute Lymphoblastic Leukemia; B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1/Phase 2
Recruitment Status
Completed
CAR-CD19 T cell therapy
Phase 2 Clinical
Keji Biomedicine (Shanghai) Co Ltd
Lymphoma, Non-Hodgkin
NCT Number
NCT03994913
NCT02933775
Intervention Type
Biological
Drug;Genetic
Indications
Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed B-cell Non-Hodgkin Lymphoma
CD19 Positive Malignant B-cell Leukemia and Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Recruiting
Unknown status
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory)
Phase 2 Clinical
Shanghai Bioray Laboratory Inc
Leukemia
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University)
Phase 2 Clinical
Suzhou University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03984968
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia, Adult B-Cell
Study Phase
Phase 2
Recruitment Status
Active, not recruiting
Anti CD19 chimeric antigen receptor T cell therapy (Beijing Boren Hospital)
Phase 2 Clinical
Beijing Boren Hospital
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04325841
NCT04340154
Intervention Type
Biological
Biological
Indications
Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoid Leukemia
Study Phase
Phase 2
Phase 2
Recruitment Status
Recruiting
Recruiting
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing)
Phase 2 Clinical
Southwest Hospital Chongqing
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT02349698
Intervention Type
Biological
Indications
Leukemia; Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR T-cell therapy (Shanghai Children's Medical Center)
Phase 2 Clinical
Shanghai Children'S Medical Center, Miltenyi Biotec
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
CART-19 cells (Henan Hualong Biotechnology)
Phase 2 Clinical
Henan Hualong Biotechnology
Leukemia, Lymphoid
Anti-CD19 CAR T cell therapy (Shanghai GeneChem)
Phase 2 Clinical
Shanghai Genechem Co Ltd
Lupus Erythematosus, Systemic, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, B-Cell
NCT Number
NCT02672501
NCT03030976
Intervention Type
Drug
Drug
Indications
Leukemia, B-Cell
Systemic Lupus Erythematosus (SLE)
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Unknown status
Unknown status
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital)
Phase 2 Clinical
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital
Leukemia
NCT Number
NCT00466531
Intervention Type
Biological;Drug
Indications
Leukemia
Study Phase
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing)
Phase 2 Clinical
Xuanwu Hospital Of Capital Medical University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03902197
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia
Study Phase
Phase 2
Recruitment Status
Recruiting
TAK-007
TAK-007
Phase 2 Clinical
University Of Texas M. D. Anderson Cancer Center
Lymphoma, B-Cell
MB-CART2019.1
MB-CART2019.1
Phase 2 Clinical
Miltenyi Biotec
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03870945
Intervention Type
Biological
Indications
B-cell Non Hodgkin Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
Coltuximab ravtansine
SAR-3419, huB4-DM4
Phase 2 Clinical
Immunogen
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT01470456
NCT01472887
NCT01440179
NCT00549185
NCT00796731
Intervention Type
Drug
Drug
Drug
Drug
Drug
Indications
Diffuse Large B-Cell Lymphoma
Diffuse Large B-cell Lymphoma
Acute Lymphocytic Leukaemia
Lymphoma; Non-Hodgkin
Lymphoma; Non-Hodgkin
Study Phase
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Terminated
Completed
Completed
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center)
Phase 2 Clinical
The University Of Texas M.D. Anderson Cancer Center
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04029038
Intervention Type
Biological;Drug
Indications
CD19 Positive; CD22 Positive; Minimal Residual Disease; Progressive Disease; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Non-Hodgkin Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Not yet recruiting
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)
Phase 2 Clinical
The First Affiliated Hospital Of Nanchang University
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma
NCT Number
NCT04196205
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia ,Lymphomas
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics)
ICTCAR-014
Phase 2 Clinical
Sidansai Biotechnology Co Ltd
Lymphoma, Non-Hodgkin
Anti-CD19 CAR-T cell therapy (Sinobioway)
Phase 2 Clinical
Sinobioway Biomedicine Co Ltd
Lymphoma, Large B-Cell, Diffuse, Lymphoma
TC-110
TC-110
Phase 2 Clinical
Tcr2 Therapeutics
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary mediastinal B cell lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04323657
Intervention Type
Drug
Indications
Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
JCAR-015
JCAR-15, JCAR-015, 19-28z-T-Cells, 19-28z+ T cells, 19-28z CAR T cells
Phase 2 Clinical
Seattle Children'S Research Institute, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, Juno Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT02535364
NCT02973191
NCT01044069
NCT01840566
NCT01416974
NCT02813252
Intervention Type
Biological
Drug
Biological
Procedure;Biological;Drug
Biological;Drug
Genetic
Indications
Acute Lymphoblastic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia; Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Leukemia
Acute Lymphoblastic Leukemia
Study Phase
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
N/A
Recruitment Status
Terminated
Withdrawn
Active, not recruiting
Active, not recruiting
Completed
Active, not recruiting
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid)
Phase 2 Clinical
Wuhan Bio-Raid Biotechnology
Hematologic Diseases, Lymphoma, B-Cell
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital)
Phase 2 Clinical
People'S Liberation Army General Hospital Military Service
Leukemia, Lymphoma
NCT Number
NCT03185494
Intervention Type
Biological
Indications
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis); Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Unknown status
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital)
Phase 2 Clinical
Pla General Hospital
Lymphoma, B-Cell
NCT Number
NCT04163302
Intervention Type
Biological
Indications
Lymphoma, B-Cell
Study Phase
Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology)
Phase 2 Clinical
Wuhan Sian Medical Technology, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03366350
Intervention Type
Procedure
Indications
Acute Lymphoblastic Leukemia; B Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
JCAR-014
JCAR-014
Phase 2 Clinical
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT01865617
NCT01593696
NCT01087294
NCT02706405
Intervention Type
Other;Biological
Biological
Procedure;Biological
Other;Biological;Drug
Indications
CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Small Lymphocytic Lymphoma
ALL; B Cell Lymphoma; Leukemia; Large Cell Lymphoma; Non-Hodgkin Lymphoma
Leukemia, B-cell; Lymphoma, Hodgkins; Lymphoma, Non-hodgkins; Lymphoma, B-Cell
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Active, not recruiting
Completed
Recruiting
Recruiting
CLIC-1901 (Ottawa Hospital Research Institute)
CLIC-1901
Phase 2 Clinical
Ottawa Hospital Research Institute
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03765177
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing)
Phase 2 Clinical
Southwest Hospital Chongqing
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT02737085
NCT02710149
Intervention Type
Biological
Biological
Indications
Lymphoma, Large B-Cell, Diffuse
Leukemia; Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Recruitment Status
Unknown status
Recruiting
PBCAR-0191
PBCAR-0191
Phase 2 Clinical
Baxalta
Hematologic Neoplasms, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin
NCT Number
NCT04649112
Intervention Type
Genetic
Indications
CD19 Expressing Malignancies; Hematologic Malignancy
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Anti-CD19 CAR-T cell therapy (Uppsala University)
Phase 2 Clinical
Uppsala University
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03068416
Intervention Type
Biological
Indications
B-cell Leukemia; B-Cell Lymphoma
Study Phase
Phase 2
Recruitment Status
Active, not recruiting
CD19 CAR-T cell therapy (Chongqing Precision Biotech)
Phase 2 Clinical
Chongqing Precision Biotechnology Co Ltd
Lymphoma, B-Cell, Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-Cell, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04271410
NCT04271800
Intervention Type
Biological
Biological
Indications
Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-cell; Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia; Lymphoma; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Recruitment Status
Recruiting
Recruiting
TI-1007
TI-1007
Phase 2 Clinical
Timmune Biotech
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT03720496
Intervention Type
Biological
Indications
Non-hodgkin Lymphoma,B Cell
Study Phase
Phase 1
Recruitment Status
Recruiting
PTG-01
PTG-01
Phase 1 Clinical
Protheragen
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology)
Phase 1 Clinical
Tianjin Mycure Medical Technology Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03671460
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells
TAK-940
Phase 1 Clinical
Takeda
Neoplasms
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology)
Phase 1 Clinical
Shanghai Longyao Biotechnology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04166838
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia (B-ALL); Safety and Efficacy of CD19 UCAR-T Cells
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering)
Phase 1 Clinical
Nagoya University, Shinshu University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.)
Phase 1 Clinical
China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital
Lymphoma, B-Cell
NCT Number
NCT03952923
Intervention Type
Biological
Indications
B-cell Malignancy
Study Phase
Phase 1
Recruitment Status
Recruiting
PCAR-019 (Anke Biotechnology)
Phase 1 Clinical
Anhui Anke Biotechnology (Group)Co Ltd
Lymphoma, Large B-Cell, Diffuse, Leukemia, Prolymphocytic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02851589
NCT02819583
NCT04184414
Intervention Type
Biological
Biological
Drug
Indications
Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; B-cell Prolymphocytic Leukemia; Diffuse Large Cell Lymphoma
Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; B-cell Prolymphocytic Leukemia; Diffuse Large Cell Lymphoma
B Acute Lymphoblastic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Early Phase 1
Recruitment Status
Unknown status
Unknown status
Recruiting
C-CAR011
Phase 1 Clinical
Pla General Hospital
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT02081937
NCT03154775
NCT03018093
NCT03299738
NCT02976857
NCT03327285
NCT01864889
Intervention Type
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Indications
Hematopoietic/Lymphoid Cancer; Non-hodgkin Lymphoma,B Cell; Mantle Cell Lymphoma
Refractory or Relapsed Non-Hodgkin Lymphoma
Relapsed or Refractory Acute Lymphoblastic Leukemia
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Acute Lymphoblastic Leukemia(ALL)
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
Recruitment Status
Unknown status
Unknown status
Unknown status
Unknown status
Completed
Active, not recruiting
Unknown status
Anti-CD19 CAR-T cell therapy (Juno Therapeutics)
Phase 1 Clinical
Juno Therapeutics
Hematologic Neoplasms
NCT Number
NCT03085173
Intervention Type
Biological
Indications
Chronic Lymphocytic Leukemia (CLL); Relapsed; Refractory
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell)
Phase 1 Clinical
Immune Cell
Lymphoma, B-Cell, Leukemia, Lymphoid, Leukemia, B-Cell
NCT Number
NCT03383952
Intervention Type
Biological
Indications
B Cell Leukemia; B Cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD22/CD19 monoclonal antibody-toxin conjugate
Phase 1 Clinical
Ut Southwestern Medical Center
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center)
Phase 1 Clinical
City Of Hope National Medical Center
Lymphoma, Non-Hodgkin
Duvortuxizumab
MGD-011, JNJ-64052781
Phase 1 Clinical
Macrogenics
Hematologic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02743546
NCT02454270
Intervention Type
Drug
Drug
Indications
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Study Phase
Phase 1
Phase 1
Recruitment Status
Withdrawn
Terminated
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital)
Phase 1 Clinical
Seattle Children'S Hospital
Precursor Cell Lymphoblastic Leukemia-Lymphoma
RO-7227166
RO-7227166
Phase 1 Clinical
F. Hoffmann-La Roche Ltd
Lymphoma, Non-Hodgkin
NCT Number
NCT04077723
Intervention Type
Drug
Indications
Lymphoma, Non-Hodgkin
Study Phase
Phase 1
Recruitment Status
Recruiting
K193 bispecific antibody
K-193
Phase 1 Clinical
Beijing Lvzhu Biological Technology Co Ltd
Lymphoma, B-Cell
AMG-562
AMG-562
Phase 1 Clinical
Amgen Inc
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
NCT Number
NCT03571828
Intervention Type
Drug
Indications
Diffuse Large B-cell Lymphoma(DLBCL); Mantle Cell Lymphoma (MCL); Follicular Lymphoma (FL)
Study Phase
Phase 1
Recruitment Status
Active, not recruiting
GNC-038
GNC-038
Phase 1 Clinical
Sichuan Baili Pharmaceutical Co Ltd
Solid tumours, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04606433
Intervention Type
Drug
Indications
Non-hodgkin Lymphoma
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
CD19.CAR-VST
CD19.CAR-VST
Phase 1 Clinical
Baylor College Of Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital)
Phase 1 Clinical
Chongqing Xinqiao Hospital
Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04264039
Intervention Type
Biological;Drug
Indications
B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma
Study Phase
Early Phase 1
Recruitment Status
Not yet recruiting
Anti-human CD19-CD22 T cell therapy
Phase 1 Clinical
Hrain Biotechnology Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology)
Phase 1 Clinical
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech)
LCAR-L10D
Phase 1 Clinical
Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT04094766
Intervention Type
Drug
Indications
Refractory B Acute Lymphoblastic Leukemia; Relapse B Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Withdrawn
UCART-19
S-68587, UCART-19
Phase 1 Clinical
Cellectis
Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02808442
NCT02735083
NCT02746952
Intervention Type
Biological
Biological
Biological
Indications
Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
Advanced Lymphoid Malignancies
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Enrolling by invitation
Completed
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University)
Phase 1 Clinical
Kunming Medical University
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03854994
NCT04289220
Intervention Type
Biological
Biological
Indications
B Cell Lymphoma; B-cell Acute Lymphoblastic Leukemia
B Cell Lymphoma; B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Not yet recruiting
CD19-STAR-T cell therapy (China Immunotech Co., Ltd.)
Phase 1 Clinical
Hebei Yanda Hospital, China Immunotech Co Ltd
Lymphoma, B-Cell
NCT Number
NCT03953599
Intervention Type
Biological
Indications
B Cell Malignancy
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University)
Phase 1 Clinical
Shanghai Jiaotong University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03919526
Intervention Type
Biological;Drug
Indications
MRD-positive; Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
iPD1 CD19 eCAR-T therapy (Marino Biotechnology)
Phase 1 Clinical
Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd
Lymphoma, B-Cell
NCT Number
NCT03208556
Intervention Type
Biological;Drug
Indications
Relapsed or Refractory B-cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Unknown status
MC-19PD1 CAR-T cell therapy (Peking University)
Phase 1 Clinical
Peking University
Lymphoma, B-Cell
NCT Number
NCT03932955
Intervention Type
Biological
Indications
Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center)
Phase 1 Clinical
Uclas Jonsson Comprehensive Cancer Center
Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04007029
Intervention Type
Biological;Drug
Indications
CD19 Positive; CD20 Positive; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Small Lymphocytic Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
GC-012F
GC-012F
Phase 1 Clinical
Genxi Biotechnology (Shanghai) Co Ltd
Multiple Myeloma
NCT Number
NCT04412889
NCT04617704
NCT04236011
Intervention Type
Biological
Biological
Biological
Indications
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Study Phase
Early Phase 1
Early Phase 1
Early Phase 1
Recruitment Status
Not yet recruiting
Not yet recruiting
Recruiting
CLBR-001/SWI-019
CLBR-001/SWI-019
Phase 1 Clinical
California Institute For Biomedical Research, Abbvie Inc
Lymphoma, B-Cell
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital)
Phase 1 Clinical
Henan Provincial Cancer Hospital
Lymphoma, B-Cell
NCT Number
NCT03881761
Intervention Type
Biological
Indications
B-Cell Lymphoma Stage I; Refractory; Relapsed
Study Phase
Phase 1
Recruitment Status
Recruiting
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)
Phase 1 Clinical
The First Affiliated Hospital Of Nanchang University
Multiple Myeloma
NCT Number
NCT04194931
Intervention Type
Biological
Indications
Relapsed or Refractory Multiple Myeloma
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19 CARvac T cell therapy (iCell Gene Therapeutics)
Phase 1 Clinical
Icell Gene Therapeutics
Lymphoma, B-Cell, Leukemia, B-Cell
NCT Number
NCT04156243
Intervention Type
Biological
Indications
B Cell Lymphoma; B Cell Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University)
Phase 1 Clinical
Stanford University
Lymphoma, B-Cell
NCT Number
NCT03233854
Intervention Type
Other;Biological;Drug
Indications
B Acute Lymphoblastic Leukemia; CD19 Positive; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly; Minimal Residual Disease; Philadelphia Chromosome Positive; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
ICT19G1
ICT-19G1
Phase 1 Clinical
Sidansai Biotechnology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Senl-1904A
Senl-1904A, Senl_1904A
Phase 1 Clinical
Hebei Senlang Biological Technology Co Ltd
Leukemia, Lymphoid, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03840317
Intervention Type
Biological
Indications
Acute Lymphocytic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19-CAR T cell therapy (Kecellitics Biotech)
Phase 1 Clinical
Kecellitics Biotech Company Ltd
Leukemia, Lymphoma
NCT Number
NCT04100187
Intervention Type
Biological
Indications
Lymphoma
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
GC007g
GC-007G
Phase 1 Clinical
Genxi Biotechnology (Shanghai) Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ET190L1-ARTEMIS T cells (Eureka Therapeutics)
ET190, ET-190, ET190L1, ET190L1-ARTEMI
Phase 1 Clinical
Eureka Therapeutics
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03379493
NCT03415399
NCT03895944
Intervention Type
Biological
Biological
Biological
Indications
Lymphomas Non-Hodgkin's B-Cell
Lymphoma, B-Cell
CD19+ Lymphoma, B-Cell; CD19+ Leukemia, B-Cell
Study Phase
Phase 1
Phase 1
Early Phase 1
Recruitment Status
Terminated
Active, not recruiting
Recruiting
A-319
A-319
Phase 1 Clinical
Generon Corp
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04056975
Intervention Type
Biological
Indications
Relapsed or Refractory B-cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Anti-CD19 redirected NK cell therapy (National University Health System, Singapore)
Phase 1 Clinical
National University Health System
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT01974479
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Suspended
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech)
Phase 1 Clinical
Timmune Biotech
Leukemia, Lymphoma, Non-Hodgkin
NCT Number
NCT03910842
Intervention Type
Biological
Indications
Non-Hodgkin Lymphoma of Intestine; Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
AFM-11
AFM-11
Phase 1 Clinical
Affimed
Leukemia, B-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT02848911
NCT02106091
Intervention Type
Drug
Drug
Indications
Leukemia, B-Cell
Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
Study Phase
Phase 1
Phase 1
Recruitment Status
Terminated
Terminated
Anti-CD19 CAR T-cell therapy (University College London)
4G7-CARD
Phase 1 Clinical
University College London
Lymphoma
NCT Number
NCT04443829
Intervention Type
Biological
Indications
Primary CNS Lymphoma
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)
Phase 1 Clinical
Zhejiang University
Multiple Myeloma
NCT Number
NCT04603872
Intervention Type
Drug
Indications
Multiple Myeloma in Relapse; Multiple Myeloma, Refractory; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphocytic Leukaemia Refractory; Non-Hodgkin's Lymphoma, Relapsed; Non-Hodgkin's Lymphoma Refractory
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering)
Phase 1 Clinical
Institute Of Hematology & Blood Diseases Hospital
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT02975687
NCT03029338
Intervention Type
Biological
Biological
Indications
Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukaemia Recurrent
Lymphomas Non-Hodgkin's B-Cell; Relapse
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Active, not recruiting
BZ019
BZ-019
Phase 1 Clinical
Shanghai Cell Therapy Research Institute
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Primary mediastinal B cell lymphoma, Lymphoma, Follicular
NCT Number
NCT04067414
NCT04250324
Intervention Type
Biological
Biological
Indications
Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Transformed Lymphoma; Primary Mediastinal Large B Cell Lymphoma
Large B-cell Lymphoma
Study Phase
Phase 1
Phase 1
Recruitment Status
Active, not recruiting
Recruiting
CD19-CAR
CD19-CAR
Phase 1 Clinical
The University Of Texas M.D. Anderson Cancer Center
Leukemia, Lymphoma
CTA-101
CTA-101
Phase 1 Clinical
Nanjing Bioheng Biotech, Xuzhou Medical University (Xzmu), Nanjing Medical University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04154709
NCT04227015
Intervention Type
Biological
Drug
Indications
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma
Study Phase
Phase 1
Early Phase 1
Recruitment Status
Recruiting
Recruiting
YTB-323
YTB-323
Phase 1 Clinical
Novartis Pharma Ag
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03960840
Intervention Type
Drug
Indications
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed)
Phase 1 Clinical
Icar Bio, China
Leukemia, Lymphoma
ET-019002
ET-019002
Phase 1 Clinical
Eureka Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03642496
Intervention Type
Biological
Indications
B-Cell Malignancies
Study Phase
Early Phase 1
Recruitment Status
Not yet recruiting
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health)
Phase 1 Clinical
Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University)
Phase 1 Clinical
First Affiliated Hospital Of Zhejiang University
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT04486872
Intervention Type
Biological
Indications
Diffuse Large B Cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
4-1BBz CD19-Her2tG (Seattle Children's Hospital)
Phase 1 Clinical
Seattle Children'S Hospital
Neoplasms
TG-1801
NI-1701, TG-1801
Phase 1 Clinical
Novimmune
Lymphoma, B-Cell
NCT Number
NCT03804996
Intervention Type
Biological;Drug
Indications
B-Cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
aCD19z
aCD19z
Phase 1 Clinical
Christie Hospital Nhs Foundation Trust
Lymphoma, Non-Hodgkin
CC-97540
CC-97540
Phase 1 Clinical
Juno Therapeutics
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
NCT Number
NCT04231747
Intervention Type
Biological
Indications
Lymphoma Non-Hodgkin; Agressive Lymphoma; Diffuse-large B-cell Lymphoma (DLBCL)
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti CD19 chimeric antigen receptor T cell therapy (Gracell Biotechnology)
Phase 1 Clinical
Genxi Biotechnology (Shanghai) Co Ltd
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04516551
Intervention Type
Biological
Indications
Relapsed Adult ALL; B Cell Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research)
WZTL002-1
Phase 1 Clinical
The Malaghan Institute Of Medical Research
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Primary mediastinal B cell lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04049513
Intervention Type
Biological;Drug
Indications
Lymphomas Non-Hodgkin's B-Cell; Diffuse Large B-cell Lymphoma (DLBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Transformed Follicular Lymphoma (TFL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL)
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital)
Phase 1 Clinical
Hebei Yanda Hospital
Lymphoma, B-Cell
NCT Number
NCT04260945
NCT04260932
Intervention Type
Biological
Biological
Indications
B-cell Leukemia
B-cell Lymphoma
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
GC-007F (Gracell Biotechnology)
GC-007F
Phase 1 Clinical
Genxi Biotechnology (Shanghai) Co Ltd
Lymphoma, B-Cell
NCT Number
NCT03825718
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology)
Phase 1 Clinical
Hrain Biotechnology
Leukemia, Lymphoid
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics)
Phase 1 Clinical
Icell Gene Therapeutics
Lymphoma, B-Cell, Leukemia, Leukemia, B-Cell
NCT Number
NCT04156178
Intervention Type
Biological
Indications
B Cell Lymphoma; B Cell Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University)
Phase 1 Clinical
Fujian Medical University
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT04215016
Intervention Type
Biological
Indications
Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
Study Phase
Phase 1
Recruitment Status
Recruiting
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center)
Phase 1 Clinical
Memorial Sloan Kettering Cancer Center
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03085173
Intervention Type
Biological
Indications
Chronic Lymphocytic Leukemia (CLL); Relapsed; Refractory
Study Phase
Phase 1
Recruitment Status
Recruiting
H-31970-SAGAN
H-31970-SAGAN
Phase 1 Clinical
Baylor College Of Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Virus-specific-CD19.CAR
Phase 1 Clinical
Baylor College Of Medicine
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Anti-CD19 chimeric antigen receptor T cell therapy (Wuhan Sian Medical Technology)
Phase 1 Clinical
Wuhan Sian Medical Technology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Murine CD19 CAR-T cell therapy (Yake)
Phase 1 Clinical
Yake Biotechnology
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04532281
Intervention Type
Drug
Indications
Acute Lymphoblastic Leukemia; Non-Hodgkin Lymphoma of Soft Tissue
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine)
Phase 1 Clinical
The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04303520
Intervention Type
Biological;Drug
Indications
CD19-positive ALL
Study Phase
Phase 1
Recruitment Status
Recruiting
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center)
Phase 1 Clinical
Fred Hutchinson Cancer Research Center
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03103971
Intervention Type
Other;Procedure;Biological;Drug
Indications
Adult B Acute Lymphoblastic Leukemia; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Adult Acute Lymphoblastic Leukemia; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Study Phase
Phase 1
Recruitment Status
Recruiting
XYF19 CAR-T cell therapy (Xijing Hospital)
Phase 1 Clinical
Xijing Hospital
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04037566
Intervention Type
Drug;Genetic
Indications
Leukemia Lymphocytic Acute (ALL) in Relapse; Leukemia Lymphocytic Acute (All) Refractory; Lymphoma, B-Cell; CD19 Positive
Study Phase
Phase 1
Recruitment Status
Recruiting
Humanized CD19 CAR-T cell therapy (Yake)
YK-C19
Phase 1 Clinical
Yake Biotechnology
Lymphoma, B-Cell, Leukemia, Lymphoid
NCT Number
NCT04532268
Intervention Type
Drug
Indications
Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma,B Cell
Study Phase
Early Phase 1
Recruitment Status
Recruiting
CD19 CAR-T (HuaDao CAR-Tcell)
Phase 1 Clinical
Huadao Car-Tcell
Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
PBLTT52CAR19
Phase 1 Clinical
Great Ormond Street Hospital For Children Nhs Foundation Trust
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04557436
Intervention Type
Drug
Indications
B Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)
Phase 1 Clinical
Icell Gene Therapeutics
Multiple Myeloma, Lymphoma
NCT Number
NCT04162353
Intervention Type
Biological
Indications
Multiple Myeloma in Relapse; Refractory Multiple Myeloma; Plasmacytoid; Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
pCAR-19B
Phase 1 Clinical
Chongqing Precision Biotechnology Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology)
Clinical
Nanjing Cart Medical Technology
Neoplasms
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology)
Clinical
Hebei Senlang Biological Technology Co Ltd
Leukemia
Anti-CD19 CAR-T cell therapy (Bioceltech)
Clinical
Bioceltech Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies)
PZ-01
Clinical
Pinze Lifetechnology
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
4G7SDIE
Clinical
Synimmune, The University Of Tubingen
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research)
Clinical
Leidos
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Anti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source)
Pending
Nonindustrial Source
Lymphoma, Non-Hodgkin
MDX 1342
MDX-1342
Pending
Medarex
Arthritis, Rheumatoid, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT00639834
NCT00593944
Intervention Type
Biological
Biological
Indications
Rheumatoid Arthritis
Chronic Lymphocytic Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Completed
PF-6883541
PF-6883541, PF-06883541
Pending
Pfizer Pharmaceuticals Ltd (China)
Neoplasms
Modified anti-CD19 T-cell therapy (Fred Hutchinson Cancer Research Center)
Pending
Fred Hutchinson Cancer Research Center
Neoplasms
DI-B4
DI-B4
Pending
Merck Serono, Cancer Research Uk
Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT01805375
Intervention Type
Drug
Indications
Indolent B-cell Lymphoma; Chronic Lymphocytic Leukaemia; Waldenström Macroglobulinaemia
Study Phase
Phase 1
Recruitment Status
Completed
FH-2494
FH-2494
Discontinued
Fred Hutchinson Cancer Research Center, National Cancer Institute
Lymphoma, B-Cell, Marginal Zone, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
CD19-specific T-cell therapy (B cell malignancies), Christie NHS Foundation Trust
Discontinued
The University Of Manchester, Cancer Research Uk, Christie Hospital Nhs Foundation Trust
Lymphoma, Non-Hodgkin
NCT Number
NCT01493453
Intervention Type
Genetic
Indications
CD19 Positive Non-Hodgkin Lymphoma
Study Phase
Phase 1
Recruitment Status
Unknown status
Taplitumomab paptox
Discontinued
University Of Minnesota
Leukemia
Oncolysin B
Discontinued
Immunogen
Leukemia, Lymphoma, Lymphoma, Non-Hodgkin
CD19CAR
CD19CAR
Discontinued
National Cancer Institute, City Of Hope National Medical Center
Leukemia, Hairy Cell, Lymphomatoid Granulomatosis, Lymphoma
NCT Number
NCT04160195
Intervention Type
Biological;Drug
Indications
Lymphoma, B-Cell; Lymphoma, Non-hodgkins; Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia
Study Phase
Phase 1
Recruitment Status
Suspended
Denintuzumab mafodotin
SGN-19A, SGN-CD19A
Discontinued
Seattle Genetics Inc
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT02855359
NCT02592876
NCT01786135
NCT01786096
Intervention Type
Drug
Drug
Drug
Drug
Indications
Diffuse, Large B-Cell, Lymphoma; Follicular Lymphoma, Grade 3b; Transformed Lymphoma / DLBCL
Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular, Grade 3b; Follicular Lymphoma, Grade 3b
Burkitt Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Study Phase
Phase 2
Phase 2
Phase 1
Phase 1
Recruitment Status
Terminated
Terminated
Completed
Completed
Monoclonal antibody B43 Genistein-conjugate
Discontinued
University Of Minnesota, Bristol-Myers Squibb Company
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT00004858
Intervention Type
Biological
Indications
Leukemia; Lymphoma
Study Phase
Phase 1
Recruitment Status
Unknown status
SGN-CD19B
SGN-CD19B
Discontinued
Seattle Genetics Inc
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
NCT Number
NCT02702141
Intervention Type
Drug
Indications
Non-Hodgkin Lymphoma; DLBCL; Diffuse Large B-cell Lymphoma; Grade 3 Follicular Lymphoma
Study Phase
Phase 1
Recruitment Status
Terminated
19-28z+
19-28z+
Discontinued
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute Inc
Leukemia